Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-05-23
2006-05-23
Woitach, Joseph (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S455000, C435S456000, C435S320100
Reexamination Certificate
active
07048920
ABSTRACT:
The invention provides melanoma cell specific adenovirus vectors, which preferentially replicate in melanoma cells.
REFERENCES:
patent: 5679511 (1997-10-01), Kwon
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5776743 (1998-07-01), Frisch
patent: 5801029 (1998-09-01), McCormick
patent: 5824543 (1998-10-01), Sun
patent: 5846945 (1998-12-01), McCormick
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6001646 (1999-12-01), Sun
patent: 6692736 (2004-02-01), Yu et al.
patent: 2003/0026789 (2003-02-01), Gregory et al.
patent: 2003/0152553 (2003-08-01), Little et al.
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 97/10007 (1997-03-01), None
patent: WO 98/29555 (1998-07-01), None
patent: WO 9829555 (1998-07-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 98/37189 (1998-08-01), None
patent: WO 09/39465 (1998-09-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 99/59604 (1999-11-01), None
patent: WO 9959604 (1999-11-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/39319 (2000-07-01), None
patent: WO 9835554 (2003-04-01), None
Duque et al., Cancer Gene Therapy, vol. 6, pp. 554-563, 1999.
Alemany, et al.Nat. Biotechnol., (2000) vol. 18: 723-727.
Hallenbeck, et al.,Hum. Gene Ther.(1999) vol. 10: 1721-1733.
Herman, Ronald C.,“Alternatives for the initiation of translation”, Trends in Biochemical Sciences, vol. 14, No. 6, Jun. 1989.
Jackson, Richard J. et al., “Internal initiation of translation in eukaryotes: The picornavirus paradigm and beyond”, RNA 1, pp. 985-1000, 1995.
Lin, Jun-Hsiang et al., “A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice”, Proc. Natnl. Acad. Sci. USA, vol. 92, pp. 679-683, Jan. 1995.
Yu, et al.Cancer Res., (1999) vol. 59: 1498-1504.
Li Yuanhao
Yu De Chao
Cell Genesys Inc.
Gray Cary US LLP
Rudnick DLA Piper
Whiteman Brian
Woitach Joseph
LandOfFree
Recombinant oncolytic adenovirus for human melanoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant oncolytic adenovirus for human melanoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant oncolytic adenovirus for human melanoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526829